Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term CHEMOTHERAPY. Found 28 abstracts

no pagination
Gustafson HL, Yao S, Goldman BH, Lee K, Spier CM, LeBlanc ML, Rimsza LM, Cerhan JR, Habermann TM, Link BK, Maurer MJ, Slager SL, Persky DO, Miller TP, Fisher RI, Ambrosone CB, Briehl MM. Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma. American journal of hematology. 2014 Jun;89(6):639-45.   PMCID: 4137041
Pond GR, Agarwal N, Bellmunt J, Choueiri TK, Qu A, Fougeray R, Vaughn D, James ND, Salhi Y, Albers P, Niegisch G, Galsky MD, Wong YN, Ko YJ, Stadler WM, O'Donnell PH, Sridhar SS, Vogelzang NJ, Necchi A, Di Lorenzo G, Sternberg CN, Mehta A, Sonpavde G. A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma. BJU international. 2014 May;113(5B):E137-E143.
Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse MA, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen L, Meropol NJ. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Annals of Oncology. 2009 Jul;20(7):1223-9.   PMCID: Private funding
Gumbs AA, Zain J, O'Connor OA. Importance of Early Splenectomy in Patients with Hepatosplenic T-Cell Lymphoma and Severe Thrombocytopenia. Annals of Surgical Oncology. 2009 Jul;16(7):2014-7.
Hesterberg PE, Banerji A, Oren E, Penson RT, Krasner CN, Seiden MV, Wong JT. Risk stratification for desensitization of patients with carboplatin hypersensitivity: Clinical presentation and management. Journal of Allergy and Clinical Immunology. 2009 Jun;123(6):1262-7.
Koch KM, Reddy NJ, Cohen RB, Lewis NL, Whitehead B, Mackay K, Stead A, Beelen AP, Lewis LD. Effects of Food on the Relative Bioavailability of Lapatinib in Cancer Patients. Journal of Clinical Oncology. 2009 Mar;27(8):1191-6.   PMCID: not NIH funded
Lango MN, Andrews GA, Ahmad S, Feigenberg S, Tuluc M, Gaughan J, Ridge JA. Postradiotherapy neck dissection for head and neck squamous cell carcinoma: pattern of pathological residual carcinoma and prognosis. Head and Neck-Journal for the Sciences and Specialties of the Head and Neck. 2009 Mar;31(3):328-37.
Stathakis S, Roland T, Papanikolaou N, Li JS, Ma C. A Prediction Study on Radiation-induced Second Malignancies for IMRT Treatment Delivery. Technology in Cancer Research & Treatment. 2009 Apr;8(2):141-7.
Arbuckle RB, Griffith NL, Iacovelli LM, Johnson PE, Jorgenson JA, Kloth DD, Lucarelli CD, Muller RJ. Continued challenges with the use of erythropoiesis-stimulating agents in patients with cancer: Perspectives and issues on policy-guided health care. Pharmacotherapy. 2008 May;28(5):1S-15S.
Berger AC, Garcia M, Hoffman JP, Regine WF, Abrams RA, Safran H, Konski A, Benson AB, MacDonald J, Willett CG. Postresection CA 19-9 Predicts Overall Survival in Patients With Pancreatic Cancer Treated With Adjuvant Chemoradiation: A Prospective Validation by RTOG 9704. Journal of Clinical Oncology. 2008 Dec;26(36):5918-22.
McMeekin DS, Walker JL, Hartenbach EM, Bookman MA, Koh WJ. Phase I trial of the treatment of high-risk endometrial cancer with concurrent weekly paclitaxel and cisplatin and whole abdominal radiation therapy: A Gynecologic Oncology Group study. Gynecologic Oncology. 2008 Jan;112(1):134-41.
Siddiqui F, Pajak TF, Watkins-Bruner D, Konski AA, Coyne JC, Gwede CK, Garden AS, Spencer SA, Jones C, Movsas B. Pretreatment quality of life predicts for locoregional control in head and neck cancer patients: A radiation therapy oncology group analysis. International Journal of Radiation Oncology Biology Physics. 2008 Feb;70(2):353-60.
Suh WW, Blackstock AW, Herman J, Konski AA, Mohiuddin M, Poggi MM, Regine WF, Cosman BC, Saltz L, Johnstone PA. ACR appropriateness criteria on resectable rectal cancer. International Journal of Radiation Oncology Biology Physics. 2008 Apr;70(5):1427-30.
Beer TM, Higano CS, Saleh M, Dreicer R, Hudes G, Picus J, Rarick M, Fehrenbacher L, Hannah AL. Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel. Investigational New Drugs. 2007 Dec;25(6):565-70.
Dreicer R, Li SL, Manola J, Haas NB, Roth BJ, Wilding G. Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the Urothelium (E3800) - A trial of the Eastern Cooperative Oncology Group. Cancer. 2007 Aug;110(4):759-63.
Emmanouilides C, Witzig TE, Wiseman GA, Gordon LI, Wang H, Schilder R, Saville MW, Flinn I, Molina A. Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-hodgkin's lymphoma. Cancer Biotherapy and Radiopharmaceuticals. 2007 Oct;22(5):684-91.
Langer C, Li SG, Schiller J, Tester W, Rapoport BL, Johnson DH. Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in eastern cooperative oncology group performance status 2 non-small-cell lung cancer patients: ECOG 1599. Journal of Clinical Oncology. 2007 Feb;25(4):418-23.
Mell LK, Malik R, Komaki R, Movsas B, Swann RS, Langer C, Antonadou D, Koukourakis M, Mundt AJ. Effect of amifostine on response rates in locally advanced non-small-cell lung cancer patients treated on randomized controlled trials: A meta-analysis. International Journal of Radiation Oncology Biology Physics. 2007 May;68(1):111-8.
Trotti A, Pajak TF, Gwede CK, Paulus R, Cooper J, Forastiere A, Ridge JA, Watkins-Bruner D, Garden AS, Ang KK, Curran W. TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group. Lancet Oncology. 2007 Jul;8(7):613-24.
Weiner LM. Emerging concepts in monocloal antibody therapy. EJC Supplements. 2007 Sep;5(5):442-3.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term CHEMOTHERAPY

CHEMOTHERAPY RADIOTHERAPY CARCINOMA SURVIVAL RADIATION-THERAPY PHASE-II PACLITAXEL BREAST-CANCER THERAPY CISPLATIN PROSTATE-CANCER NECK-CANCER ELDERLY-PATIENTS TRANSITIONAL-CELL CARCINOMA CLINICAL-TRIALS PROGNOSTIC-FACTORS radiotherapy RADIOIMMUNOTHERAPY PHASE-II TRIAL FLUOROURACIL RECURRENT CONCURRENT PHARMACOKINETICS ABSORPTION LEUKEMIA GW572016 PLUS IRINOTECAN VINFLUNINE OVARIAN-CANCER IMRT ESCALATION SENSITIZER CMS guidelines POSTOPERATIVE RADIOTHERAPY REGIMENS SINGLE GROUP FUNCTIONAL ASSESSMENT DOSE-RESPONSE DESOXYEPOTHILONE-B Urology & Nephrology ANAPHYLAXIS progression-free survival at HODGKINS-DISEASE PLUS ANTIGENS prognosis DISEASE protection advanced urothelial cancer DOCETAXEL TRACT TRIAL INFLAMMATORY-BOWEL-DISEASE GROUP RTOG BONE-MARROW B-CELL LYMPHOMA Second malignancy residual microscopic disease CYTOPROTECTOR AMIFOSTINE SQUAMOUS-CELL CARCINOMAS role GEMCITABINE anemia alfa PROTOCOL POOLED ANALYSIS IODINE I-131 TOSITUMOMAB metastatic Advanced endometrial cancer erythropoiesis-stimulating agents VALIDITY CANCER MEALS ibritumomab tiuxetan radioimmunotherapy-non-Hodgkin's lymphoma-elderly radiation therapy 6 months head and neck cancer 3D-CRT second-line therapy ESAs HUMANS Cisplatin INFLIXIMAB THERAPY IONIZING-RADIATION prostate cancer RANDOMIZED-TRIAL IMMUNOTHERAPY Whole abdominal OROPHARYNGEAL CANCER response national coverage determination NSCLC CHEMORADIATION CELL LUNG-CANCER CURATIVE RESECTION TUMOR METASTASES Conventional radiotherapy ALLERGY TOXICITY phase 2 trial neck CHOP METASTATIC COLORECTAL-CANCER ixabepilone epoetin response rate HYPERFRACTIONATED RADIATION IRINOTECAN colorectal cancer FEASIBILITY chemotherapy REGIMEN health-related quality of life ADVANCED HEAD Paclitaxel SERUM CA-19-9 PREOPERATIVE RADIOTHERAPY amifostine FOLLOW-UP FOLLICULAR LYMPHOMA NODE-POSITIVE HEAD prognostic COMBINED-MODALITY THERAPY REPLACEMENT locoregional control BLOCKADE drug allergy Desensitization-carboplatin-ovarian cancer-skin testing-hypersensitivity Hematology LEUCOVORIN urothelial carcinoma BLADDER-CANCER EXPERIENCE darbepoetin alfa HUMAN TUMOR XENOGRAFTS EPOETIN squamous cell carcinoma of the head and VINDESINE EXPRESSION MULTICENTER NAD(P)H OXIDASE ADENOCARCINOMA Centers for Medicare and Medicaid Services ABDOMINOPELVIC IRRADIATION CROHNS-DISEASE LEUKEMIA RISK non-small-cell lung cancer neck dissection LYMPHOMA
Last updated on Friday, December 06, 2019